Profectus BioSciences, Inc. Receives NIAID Grant to Develop a Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses
Published: May 02, 2012
BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases, and the Galveston National Laboratory (GNL) at the University of Texas Medical Branch at Galveston announced today that they have received a 5 year $5.4 M grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). The grant will support development of a trivalent vaccine to protect against infection with all major strains of Ebola and Marburg viruses, the two members of the filovirus family of hemorrhagic fever viruses. These agents are classified as Category A Priority Pathogens by the NIAID/NIH and CDC, and there are presently no pre- or post-exposure interventions available in the event of natural outbreak, laboratory accident, or deliberate misuse. Public health concern is based on both the emerging infectious disease status of these viruses and their potential use as biological weapons.